On April 23, 2022, the "Expert Consensus Tour of Antineoplastic Drug-Induced Bone Marrow Suppression Integrative Medicine Diagnosis and Treatment·Wuhan Station" hosted by the CSCO Expert Committee on Integrative Traditional Chinese and Western Medicine and undertaken by Hubei Mengyang Pharmaceutical Co., Ltd. was grandly held in the cloud , attracted nearly 4,000 people to watch online.

The meeting was chaired by Professor Hua Haiqing from the General Hospital of the Eastern Theater Command of the People's Liberation Army and Professor Yuan Xianglin from Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology. Jiang Ziyu, Deputy Director of Jiangsu Provincial Hospital of Integrated Traditional Chinese and Western Medicine, Tian Shaodan, Director of Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine, Liu Shuo, Director of Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Cheng Yuan, Deputy Director of the Eastern Theater General Hospital of the PLA, Professor Guo Yong of Zhejiang Provincial Hospital of Traditional Chinese Medicine, Xinjiang Uygur Autonomous Region Professor Zhang Hongliang from the Hospital of Traditional Chinese Medicine, Director Zheng Zhi from Jiangxi Provincial People's Hospital, and many other lecturers and panelists reported and discussed the progress of diagnosis and treatment of related diseases with the theme of "Integrating Chinese and Western Medicine, Keeping Upright and Innovating".

At the meeting, Jiang Ziyu, deputy director of Jiangsu Provincial Hospital of Integrated Traditional Chinese and Western Medicine, interpreted the "Expert Consensus on the Diagnosis and Treatment of Bone Marrow Suppression Caused by Antineoplastic Drugs" edited by the special committee. The four aspects of the drugs and risk factors causing myelosuppression, the pathogenesis of myelosuppression and TCM pathogenesis, the diagnosis and grading standards of TCM and Western medicine for myelosuppression, and the treatment principles and schemes of TCM and Western medicine for myelosuppression were elaborated. During the consensus interpretation process, Director Jiang highlighted the advantages of Shengbai Oral Liquid (Mixture) being widely used in myelosuppressive treatment according to the level of evidence-based medicine.

In 2019, Shengbai Oral Liquid (Mixture) was included in the Interpretation of Traditional Chinese Medicine Diagnosis and Treatment Plans and Paths for Predominant Diseases of Blood Diseases. In order to develop expert and organizational advantages and promote the clinical value of traditional Chinese medicine in the diagnosis and treatment of blood diseases, Beijing Director Tian Shaodan from Dongzhimen Hospital of University of Traditional Chinese Medicine shared "Interpretation of TCM Diagnosis and Treatment Plans and Paths for Predominant Blood Diseases" at the meeting. When talking about the application of traditional Chinese medicine decoction to treat leukopenia according to the degree of leukopenia and the patient's symptoms, it is proposed that among the listed Chinese patent medicines, there are not many Chinese patent medicines that correspond to prescriptions and syndromes, medicine syndromes, and medicines and diseases. Among the Chinese patent medicines with the above requirements, Shengbai oral liquid (mixture) meets the requirements of syndrome differentiation and application of traditional Chinese medicine decoction in terms of functions and indications, as well as prescription preparation.

Then, Liu Shuo, director of Guang'anmen Hospital of China Academy of Chinese Medical Sciences, shared the "Clinical Research Progress of Shengbai Oral Liquid (Mixture)". Director Liu gave a vivid and specific explanation of the mechanism of action of Shengbai Oral Liquid (Mixture) based on the results of modern pharmacological research. Through the report on the results of preclinical research and RCT evaluation after listing, the participating experts had a deep understanding of the product. effectiveness and safety.

In the case sharing session, Deputy Director Cheng Yuan from the General Hospital of the Eastern Theater Command of the PLA explained 6 typical effective cases of Shengbai oral liquid (mixture) in the prevention and treatment of myelosuppression caused by chemotherapy, and concluded that Shengbai oral liquid (mixture) is effective in the prevention and treatment of cancer patients Myelosuppression after chemotherapy has a clear curative effect and is safe to use.

The meeting specially set up a session of "Chinese and Western Discussion, Academic Discussion". Professor Guo Yong of Zhejiang Provincial Hospital of Traditional Chinese Medicine, Professor Zhang Hongliang of Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine, and Director Zheng Zhi of Jiangxi Provincial People's Hospital jointly discussed the new ideas and new ways to prevent and treat myelosuppression with the combination of traditional Chinese and Western medicine. Methods, and put forward expectations and prospects for the treatment of malignant tumor-related diseases with integrated traditional Chinese and Western medicine.

This expert consensus lecture tour gathered many experts in the field of integrated traditional Chinese and Western medicine, creating a professional platform for academic exchanges and scientific research discussions for medical colleagues. The successful conclusion of the first stop of the lecture tour is just the beginning. Mengyang Pharmaceutical will continue to fully support the academic promotion of the CSCO Expert Committee on Integrative Traditional Chinese and Western Medicine, and is committed to creating a professional academic exchange platform to further improve the treatment of malignant tumors with integrated traditional Chinese and Western medicine. It can reduce the incidence of toxic and side effects of tumor-related treatment, improve the quality of life of patients, and contribute to ensuring medical safety.